Allergan, Inc. is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets. The Company operates in two segments: specialty pharmaceuticals and medical devices. The specialty pharmaceuticals segment produces products, including ophthalmic products for dry eye, glaucoma, inflammation, infection, allergy and retinal disease; Botox for therapeutic and aesthetic indications; skin care products for acne, psoriasis, eyelash growth and prescription and OTC skin care products, and urologics products. The medical devices segment produces medical devices, including breast implants for augmentation, revision and reconstructive surgery and tissue expanders, and facial aesthetics products.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Drugs - Generic
- Sub-Industry: Pharmaceuticals
- Symbol: NYSE:AGN
- CUSIP: 01849010
- Web: www.allergan.com
- Market Cap: $82.77778 billion
- Outstanding Shares: 335,867,000
- 50 Day Moving Avg: $230.38
- 200 Day Moving Avg: $227.81
- 52 Week Range: $184.50 - $261.27
Sales & Book Value:
- Trailing P/E Ratio: 7.76
- Foreward P/E Ratio: 13.76
- P/E Growth: 1.24
- Annual Revenue: $14.74 billion
- Price / Sales: 5.67
- Book Value: $209.35 per share
- Price / Book: 1.19
- Annual Dividend: $2.80
- Dividend Yield: 1.1%
- EBIDTA: $5.8 billion
- Net Margins: 82.42%
- Return on Equity: 7.29%
- Return on Assets: 4.08%
- Debt-to-Equity Ratio: 0.37%
- Current Ratio: 1.32%
- Quick Ratio: 1.23%
- Average Volume: 2.30 million shs.
- Beta: 1.16
- Short Ratio: 2.45
Frequently Asked Questions for Allergan PLC. (NYSE:AGN)
What is Allergan PLC.'s stock symbol?
Allergan PLC. trades on the New York Stock Exchange (NYSE) under the ticker symbol "AGN."
How often does Allergan PLC. pay dividends? What is the dividend yield for Allergan PLC.?
Allergan PLC. declared a quarterly dividend on Friday, May 5th. Stockholders of record on Thursday, May 18th will be given a dividend of $0.70 per share on Thursday, June 15th. This represents a $2.80 annualized dividend and a dividend yield of 1.12%. The ex-dividend date is Tuesday, May 16th. View Allergan PLC.'s Dividend History.
How were Allergan PLC.'s earnings last quarter?
Allergan PLC. (NYSE:AGN) posted its quarterly earnings results on Tuesday, May, 9th. The company reported $3.35 earnings per share for the quarter, topping the Zacks' consensus estimate of $3.32 by $0.03. The business earned $3.57 billion during the quarter, compared to analyst estimates of $3.53 billion. Allergan PLC. had a return on equity of 7.29% and a net margin of 82.42%. The business's quarterly revenue was up 5.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted $3.04 EPS. View Allergan PLC.'s Earnings History.
When will Allergan PLC. make its next earnings announcement?
What guidance has Allergan PLC. issued on next quarter's earnings?
Allergan PLC. issued an update on its FY17 earnings guidance on Tuesday, May, 9th. The company provided EPS guidance of $15.85-16.35 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $16.01.
Where is Allergan PLC.'s stock going? Where will Allergan PLC.'s stock price be in 2017?
17 brokerages have issued 12 month target prices for Allergan PLC.'s shares. Their forecasts range from $205.00 to $400.00. On average, they expect Allergan PLC.'s stock price to reach $273.00 in the next year. View Analyst Ratings for Allergan PLC..
What are analysts saying about Allergan PLC. stock?
Here are some recent quotes from research analysts about Allergan PLC. stock:
- 1. Leerink Swann analysts commented, "AGN modestly beat our 4Q topline forecast (+1.3%) while Non-GAAP EPS beat our forecast by +3.8%. Given the 4Q strength of AGN's aesthetic franchises we're modestly raising our sales and EPS estimates." (2/9/2017)
- 2. According to Zacks Investment Research, "Allergan is reshaping its portfolio through acquisitions/divestitures. Allergan has been pretty active on the acquisition front and made six new product acquisitions in the third quarter. With the Allergan, Inc. acquisition, the company finds itself among the top 10 pharmas worldwide based on sales. Moreover, with the closing of the Teva deal, the company’s restructured and simplified business is encouraging. As a result, Allergan can now focus on the branded segment and is using the proceeds to buy back shares, pay down debt and pursue additional deals. Biosimilars also represent significant opportunity. Also, Allergan’s shares outperformed the generic industry in past six months. However, while we remain optimistic about the company’s growth prospects, the company is facing generic threat for Namenda IR as well as patent challenges for some of the other products in its branded portfolio, which concerns us." (1/3/2017)
Who are some of Allergan PLC.'s key competitors?
Some companies that are related to Allergan PLC. include Amgen (AMGN), Sanofi (SNY), Medtronic PLC (MDT), Bayer AG (BAYRY), AbbVie (ABBV), Novo Nordisk A/S (NVO), GlaxoSmithKline PLC (GSK), Celgene Corporation (CELG), Bristol-Myers Squibb Company (BMY), Eli Lilly and Company (LLY), Gilead Sciences (GILD), Astrazeneca PLC (AZN), Abbott Laboratories (ABT), Thermo Fisher Scientific (TMO), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Stryker Corporation (SYK) and Shire PLC (SHPG).
Who owns Allergan PLC. stock?
Allergan PLC.'s stock is owned by many different of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (0.00%), State Street Corp (4.74%), Janus Capital Management LLC (1.13%), Bank of New York Mellon Corp (1.09%), Veritas Asset Management LLP (0.00%) and TIAA CREF Investment Management LLC (0.00%). Company insiders that own Allergan PLC. stock include Brent L Saunders, Maria Teresa Hilado, Nesli Basgoz and Paul Bisaro. View Institutional Ownership Trends for Allergan PLC..
Who sold Allergan PLC. stock? Who is selling Allergan PLC. stock?
Allergan PLC.'s stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Vanguard Group Inc., Baupost Group LLC MA, Paulson & CO. Inc., Macquarie Group Ltd., TCW Group Inc., TIAA CREF Investment Management LLC and Saba Capital Management L.P.. Company insiders that have sold Allergan PLC. stock in the last year include Nesli Basgoz and Paul Bisaro. View Insider Buying and Selling for Allergan PLC..
Who bought Allergan PLC. stock? Who is buying Allergan PLC. stock?
Allergan PLC.'s stock was purchased by a variety of institutional investors in the last quarter, including Veritas Asset Management LLP, Iridian Asset Management LLC CT, Renaissance Technologies LLC, Blue Ridge Capital L.L.C., First Manhattan Co., Canyon Capital Advisors LLC, Schroder Investment Management Group and Swiss National Bank. Company insiders that have bought Allergan PLC. stock in the last two years include Brent L Saunders, Maria Teresa Hilado and Paul Bisaro. View Insider Buying and Selling for Allergan PLC..
How do I buy Allergan PLC. stock?
Shares of Allergan PLC. can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Allergan PLC.'s stock price today?
MarketBeat Community Rating for Allergan PLC. (NYSE AGN)MarketBeat's community ratings are surveys of what our community members think about Allergan PLC. and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Allergan PLC. stock can currently be purchased for approximately $248.91.
Consensus Ratings for Allergan PLC. (NYSE:AGN) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||5 Hold Ratings, 12 Buy Ratings|
|Consensus Rating:||Buy (Score: 2.71)|
|Consensus Price Target: ||$273.00 (9.68% upside)|
Analysts' Ratings History for Allergan PLC. (NYSE:AGN)
(Data available from 6/27/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|6/16/2017||Cantor Fitzgerald||Initiated Coverage||Neutral -> Neutral||$231.00||Low|
|6/12/2017||Royal Bank Of Canada||Set Price Target||Buy||$284.00||Low|
|6/9/2017||Mizuho||Lower Price Target||Buy -> Buy||$275.00 -> $267.00||Medium|
|6/8/2017||Cowen and Company||Set Price Target||Buy||$400.00||Medium|
|5/25/2017||Sanford C. Bernstein||Reiterated Rating||Outperform||Low|
|5/10/2017||Goldman Sachs Group, Inc. (The)||Downgrade||Buy -> Neutral||$262.00||High|
|4/24/2017||Citigroup Inc.||Boost Price Target||Buy||$261.00||Low|
|3/28/2017||Deutsche Bank AG||Boost Price Target||Buy||$262.00 -> $265.00||Low|
|2/22/2017||Piper Jaffray Companies||Set Price Target||Hold||$205.00||N/A|
|2/14/2017||Credit Suisse Group||Reiterated Rating||Buy||$274.00||N/A|
|2/9/2017||Leerink Swann||Boost Price Target||Buy||$280.00||N/A|
|12/23/2016||Bank of America Corporation||Reiterated Rating||Buy||$280.00||N/A|
|12/6/2016||Argus||Reiterated Rating||Buy||$340.00 -> $260.00||N/A|
|12/5/2016||J P Morgan Chase & Co||Set Price Target||Buy||$300.00||N/A|
|11/21/2016||William Blair||Reiterated Rating||Market Perform||N/A|
|11/3/2016||Morgan Stanley||Lower Price Target||Overweight||$300.00 -> $274.00||N/A|
|10/31/2016||Barclays PLC||Reiterated Rating||Equal Weight||$250.00||N/A|
|6/10/2016||Wells Fargo & Company||Reiterated Rating||Buy||N/A|
|4/12/2016||S&P Equity Research||Reiterated Rating||Buy||N/A|
|4/7/2016||Raymond James Financial, Inc.||Lower Price Target||Outperform||$317.00 -> $275.00||N/A|
|4/7/2016||Canaccord Genuity||Reiterated Rating||Buy||N/A|
|4/7/2016||Susquehanna Bancshares Inc||Downgrade||Positive -> Neutral||$345.00 -> $275.00||N/A|
|4/5/2016||Nomura||Reiterated Rating||Buy||$350.00 -> $330.00||N/A|
Earnings History for Allergan PLC. (NYSE:AGN)Earnings History by Quarter for Allergan PLC. (NYSE AGN)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/7/2017|| || || || || || || || |
|5/9/2017||Q1 2017||$3.32||$3.35||$3.53 billion||$3.57 billion||View||Listen|
|2/8/2017||Q416||$3.76||$3.90||$3.77 billion||$3.86 billion||View||Listen|
|11/2/2016||Q316||$3.57||$3.32||$3.73 billion||$3.62 billion||View||Listen|
|8/8/2016||Q216||$3.34||$3.35||$4.10 billion||$3.68 billion||View||Listen|
|5/10/2016||Q116||$3.03||$3.04||$3.97 billion||$3.80 billion||View||Listen|
|2/22/2016||Q415||$3.36||$3.41||$4.20 billion||$4.20 billion||View||Listen|
|11/4/2015||Q315||$3.20||$3.48||$5.71 billion||$4.10 billion||View||N/A|
|8/6/2015||Q215||$4.41||$4.41||$5.71 billion||$5.76 billion||View||N/A|
|11/5/2014||Q414||$1.83||$2.17||$1.90 billion||$1.91 billion||View||N/A|
|8/5/2014||Q314||$1.76||$1.78||$1.78 billion||$1.79 billion||View||Listen|
|7/21/2014||Q214||$1.44||$1.51||$1.77 billion||$1.83 billion||View||N/A|
|4/30/2014||Q114||$1.13||$1.18||$1.60 billion||$1.65 billion||View||N/A|
|2/4/2014||Q413||$1.34||$1.12||$1.65 million||$1.66 million||View||N/A|
|10/29/2013||Q313||$1.20||$1.23||$1.53 billion||$1.23 billion||View||Listen|
|7/31/2013||Q2 2013||$1.20||$1.22||$1.56 billion||$1.60 billion||View||N/A|
|5/1/2013||Q1 2013||$0.96||$0.98||$1.44 billion||$1.46 billion||View||N/A|
|2/5/2013||Q4 2012||$1.20||$1.15||$1.51 million||$1.48 million||View||N/A|
|10/30/2012||Q312||$1.04||$1.06||$1.43 billion||$1.39 billion||View||N/A|
Earnings Estimates for Allergan PLC. (NYSE:AGN)
2017 EPS Consensus Estimate: $16.04
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Current Dividend Information for Allergan PLC. (NYSE:AGN)
|Most Recent Dividend:||6/15/2017|
|Dividend Growth:||0.00% (3 Year Average)|
|Payout Ratio:||9.63% (Trailing 12 Months of Earnings) |
17.39% (Based on This Year's Estimates)
15.48% (Based on Next Year's Estimates)
Dividend History by Quarter for Allergan PLC. (NYSE AGN)
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Insider Trading and Institutional Ownership History for Allergan PLC. (NYSE:AGN)
Insider Ownership Percentage: 0.36%Insider Trades by Quarter for Allergan PLC. (NYSE:AGN)
Institutional Ownership Percentage: 84.63%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|5/18/2017||Nesli Basgoz||Director||Sell||1,889||$220.45||$416,430.05|| |
|3/2/2017||Paul Bisaro||Director||Sell||70,000||$246.68||$17,267,600.00|| |
|12/8/2016||Nesli Basgoz||Director||Sell||500||$188.72||$94,360.00|| |
|11/21/2016||Brent L. Saunders||CEO||Buy||5,250||$189.13||$992,932.50|| |
|11/11/2016||Maria Teresa Hilado||CFO||Buy||1,422||$210.64||$299,530.08|| |
|6/2/2016||Maria Teresa Hilado||CFO||Buy||661||$241.57||$159,677.77|| |
|5/11/2016||Nesli Basgoz||Director||Sell||459||$225.10||$103,320.90|| |
|12/7/2015||Nesli Basgoz||Director||Sell||2,300||$312.96||$719,808.00|| |
|8/24/2015||Paul Bisaro||Chairman||Buy||1,000||$297.42||$297,420.00|| |
|8/21/2015||Brent L Saunders||CEO||Buy||1,000||$301.94||$301,940.00|| |
|4/22/2014||Scott Sherman||EVP||Sell||14,500||$155.82||$2,259,390.00|| |
|2/21/2014||Louis Lavigne, Jr.||Director||Sell||5,400||$125.79||$679,266.00|| |
|2/19/2014||Dawn Hudson||Director||Sell||4,200||$126.35||$530,670.00|| |
|2/19/2014||Jeffrey Edwards||CFO||Sell||38,900||$126.39||$4,916,571.00|| |
|2/19/2014||Raymond Diradoorian||EVP||Sell||23,000||$126.66||$2,913,180.00|| |
|2/18/2014||Scott Sherman||EVP||Sell||5,001||$125.74||$628,825.74|| |
|1/14/2014||Scott Whitcup||VP||Sell||42,000||$117.80||$4,947,600.00|| |
|12/27/2013||Julian Gangolli||VP||Sell||52,500||$110.05||$5,777,625.00|| |
|12/20/2013||Scott Whitcup||VP||Sell||33,000||$108.80||$3,590,400.00|| |
|10/15/2013||Trevor Jones||Director||Sell||2,000||$90.14||$180,280.00|| |
|9/16/2013||Trevor Jones||Director||Sell||2,000||$89.78||$179,560.00|| |
|8/15/2013||Trevor Jones||Director||Sell||2,000||$89.89||$179,780.00|| |
|8/6/2013||Jeffrey Edwards||CFO||Sell||69,200||$91.17||$6,308,964.00|| |
|7/15/2013||Trevor M Jones||Director||Sell||2,000||$91.15||$182,300.00|| |
|6/17/2013||Trevor M Jones||Director||Sell||2,000||$101.25||$202,500.00|| |
|5/15/2013||Trevor M Jones||Director||Sell||2,000||$103.40||$206,800.00|| |
|5/9/2013||Jeffrey L Edwards||CFO||Sell||84,000||$103.49||$8,693,160.00|| |
|11/26/2012||Trevor M Jones||Director||Sell||2,500||$91.30||$228,250.00|| |
|10/5/2012||David E I Pyott||CEO||Sell||616,300||$93.73||$57,765,799.00|| |
Headline Trends for Allergan PLC. (NYSE:AGN)
Latest Headlines for Allergan PLC. (NYSE:AGN)
Allergan PLC. (AGN) Chart for Tuesday, June, 27, 2017